Knowledge · Topics
Oncology
What research exists in the context of oncology?
A degree of caution is essential here. The vast majority of findings come from cell culture and animal studies; no conclusions about human applications can be drawn from these.
1. Which Substances Have Been Studied in This Context
The overview shows how many studies exist per substance and type of investigation. A single study may be assigned to multiple topics—therefore, the numbers cannot be summed but instead describe this specific subset.
| Substance | in humans | of which controlled | human tissue | preliminary work |
|---|---|---|---|---|
| Chronic inflammation | 946 | 95 | 22 | 832 |
| Gut microbiome | 572 | 44 | 30 | 539 |
| Vitamin D | 352 | 52 | 13 | 159 |
| Turmeric and curcumin | 341 | 59 | 68 | 914 |
| Adaptogens | 187 | 37 | 64 | 652 |
| Humic acid complexes | 7 | 0 | 4 | 64 |
2. All Substances and Therapies with Controlled Studies on Oncology
84 substance and therapy pages assign controlled human studies to this area. The number comes from each page; one study can belong to several areas.
3. The Most Robust Studies
Ranked by evidential strength, not by prominence.
Controlled Human Trial
- 1 Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial (2019)
- 2 Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2 (2013)
- 3 Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD) (2019)
- 4 Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial (2010)
- 5 The spice for joint inflammation: anti-inflammatory role of curcumin in treating osteoarthritis (2016)
- 6 Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans (2015)
- 7 Short-term Curcuminoid Supplementation for Chronic Pulmonary Complications due to Sulfur Mustard Intoxication: Positive Results of a Randomized Double-Blind Trial (2015)
- 8 Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective study (2018)
- 9 Endotoxins and Non-Alcoholic Fatty Liver Disease (2021)
- 10 Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials (2023)
- 11 Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers (2013)
- 12 Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments (2020)
- 13 A Narrative Review of the Evidence for Variations in Serum 25-Hydroxyvitamin D Concentration Thresholds for Optimal Health (2022)
- 14 Aidi Injection Plus Platinum-Based Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Meta-Analysis of 42 RCTs Following the PRISMA Guidelines (2018)
- 15 Protective Effects of Salidroside on Epirubicin-Induced Early Left Ventricular Regional Systolic Dysfunction in Patients with Breast Cancer (2012)
- 16 Randomised Placebo-Controlled Pilot Clinical Trial on the Efficacy of an Ayurvedic Treatment Regimen in COVID-19 Positive Patients (2021)
- 17 Colloidal Submicron-Particle Curcumin Exhibits High Absorption Efficiency: A Double-Blind, Three-Way Crossover Study (2015)
- 18 Effects of Curcuminoids on Systemic Inflammation and Quality of Life in Patients with Colorectal Cancer Undergoing Chemotherapy: A Randomised Controlled Trial (2021)
- 19 Effects of Dietary Polyphenol Curcumin Supplementation on Metabolic, Inflammatory, and Oxidative Stress Indices in Patients with Metabolic Syndrome: A Randomised Controlled Trial (2023)
- 20 Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 2 (2006)
Sources
- 1Howells LM, Iwuji COO, Irving GRB, Barber S, Walter H, Walter H et al. · 2019
- 2Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR et al. · 2013
- 3Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M et al. · 2019
- 4Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA, Figueras C et al. · 2010
- 5
- 6Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S et al. · 2015
- 7Panahi Y, Ghanei M, Bashiri S, Hajihashemi A, Sahebkar A · 2015
- 8Pastorelli D, Fabricio ASC, Giovanis P, D'Ippolito S, Fiduccia P, Soldà C et al. · 2018
- 9Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K et al. · 2021
- 10Panknin TM, Howe CL, Hauer M, Bucchireddigari B, Rossi AM, Funk JL · 2023
- 11Volak LP, Hanley MJ, Masse G, Hazarika S, Harmatz JS, Badmaev V et al. · 2013
- 12Tandon N, Yadav SS · 2020
- 13Grant WB, Al Anouti F, Boucher BJ, Dursun E, Gezen-Ak D, Jude EB et al. · 2022
- 14Wang J, Li G, Yu L, Mo T, Wu Q, Zhou Z · 2018
- 15Zhang H, Shen WS, Gao CH, Deng LC, Shen D · 2012
- 16Devpura G, Tomar BS, Nathiya D, Sharma A, Bhandari D, Haldar S et al. · 2021
- 17Sunagawa Y, Hirano S, Katanasaka Y, Miyazaki Y, Funamoto M, Okamura N et al. · 2015
- 18Panahi Y, Saberi-Karimian M, Valizadeh O, Behnam B, Saadat A, Jamialahmadi T et al. · 2021
- 19
- 20Sagar SM, Yance D, Wong RK · 2006
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.